Vera Therapeutics is a clinical-stage biotechnology company focused on treatments for serious immunological and inflammatory diseases. Its lead program centers on atacicept, a dual inhibitor of BAFF and APRIL, studied primarily in IgA nephropathy and related autoimmune kidney disease. The company aims to modify disease progression rather than only manage symptoms, targeting underserved patients in nephrology and immunology. As a development-stage biotech, its value proposition rests on clinical data and pipeline progress rather than commercial product sales.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -76.5 | — |
| Q3 2025 | 0 | — | -80.3 | — |
| Q4 2025 | 0 | — | -91.1 | — |
| Q1 2026 | 0 | — | -121 | — |
| Q2 2026 | 0 | — | -109.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: PENN Entertainment, Inc. (PENN), BioCryst Pharmaceuticals, Inc. (BCRX), City Holding Company (CHCO), Porch Group, Inc. (PRCH), Aehr Test Systems, Inc. (AEHR), Werner Enterprises, Inc. (WERN)